Native Meta creative and exact outbound link observed October 22, 2026. Redirects were followed to the captured public destination. Advertiser claims are source material; activity does not establish performance. No personal, health or payment details were entered.

A treatment offer develops through customer stories, product education, the care process and a clear purchase entry. Compare the creative with the destination and explore the other ads sharing this route.
Selected for its design and offer structure. Ad performance isn’t available in this collection.
The yo-yo cycle is a problem many people recognize instantly from their own history, so the headline does the most important job an ad has: it opens on something the viewer already knows they've lived through. The layout is clean and easy to scan, with the headline, three supports, the price badge and the button stacked in reading order. The gold seal makes the price feel like a special without shouting.
The headline trails off with an ellipsis and never gets an answer. The three supports underneath don't say how they relate to breaking a cycle, so the viewer has to connect a community, a care team and classes to the problem on their own. Finish the thought with a line that ties the supports to what was missing last time (for example, support between appointments) and add a review from a member who describes it, attributed as their experience.
It opens on a frustration many viewers recognize from their own past attempts.
The supports suggest what's different this time, though the link isn't spelled out.
The product and price sit together on the right, separate from the message on the left.
It points to the link below and frames the step as an eligibility check.
Tirzepatide at $166/month (if approved), with fine print noting a three-month minimum that automatically renews for $499 every 11 weeks until cancelled.
The ad sends people to tirzepatidewoo.brellohealth.com, a dedicated Tirzepatide offer page rather than the homepage or a quiz, and it's one of 18 Brello ads in the library that point there. The page supports the three check marks: the plan and purchase entry lists the supportive private community, provider health review and fitness and nutrition classes, and the care process section ends on ongoing support. It doesn't pick up the yo-yo cycle itself. The treatment education section talks about routines getting busy and staying consistent, which is the nearest echo, and putting that idea in the hero would let the page answer the question this ad leaves hanging.
Brello's dedicated Tirzepatide offer page opens on a $166 a month special with the three-month plan box, then moves through reviews, treatment education, a four-step care path, inclusions and FAQs. It's where 18 Brello ads in the library land, all static image ads, built on emotional moments, native-style text posts and offer or inclusion lists.
A price lock banner, the vial with a $166 badge, and a plan box with the $499 three-month plan, Trustpilot rating, transfer note and intake explanation, answering what it costs and what happens when you pay.
Trusted by 80,000+ members with a Trustpilot rating and review cards about community, customer service and members' own results, answering whether people like you have done this.
A deeper look inside Tirzepatide, with a short explanation, a list of what studies examine, footnoted sources and a results-may-vary note, answering what the medication is.
A straightforward path to care in four photo steps (select your plan, provider review, ships to your door, ongoing support), answering how the process works.
What makes Brello different, with six inclusions beside a photo and a Take the First Step button, answering what you get beyond the medication.
Six questions on approval, refunds, timelines and replacements, then the study references, disclaimers and plan terms, answering the last practical doubts.
Read the full breakdown of this page
One of 22 Brello Health ads in the Fluid Inspiration Library, captured from the Meta Ad Library on Oct 22, 2026. We record that an ad ran publicly, not how it performed.